Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
doi:10.3389/fphar.2022.1026182
How does BPC-157 compare with TB-500
If BPC-157 failed in the one controlled human trial that was actually conducted, that failure is invisible
The much larger, headline-grabbing numbers associated with cagrilintide in the press figures in the low-to-mid 20% range come from Phase 3 trials of CagriSema , the combination with semaglutide, and are company-reported topline results, not standalone-cagrilintide data and not the peer-reviewed Phase 2 result cited above
US$ 20.24
US$ 28.83
US$ 23.79
US$ 22.90
